论文部分内容阅读
目的探讨冲击量重组人促红细胞生成素(rhEPO)对乳腺癌患者化疗所致贫血的临床疗效和毒副作用。方法43例因化疗导致贫血的乳腺癌患者,随机分为治疗组(23例)和对照组(20例),治疗组予冲击量rhEPO治疗10d,并予口服铁剂,而对照组仅予口服铁剂治疗。结果4周后评价血红蛋白量、红细胞比容、网织红细胞计数及生活质量评分等,治疗组均优于对照组,差异有统计学意义,而不良反应可耐受。结论冲击量rhEPO治疗乳腺癌化疗所致贫血安全、有效。
Objective To investigate the clinical effects and toxicities and side effects of recombinant human recombinant human erythropoietin (rhEPO) on patients with breast cancer undergoing chemotherapy-induced anemia. Methods Forty-three patients with breast cancer who had anemia caused by chemotherapy were randomly divided into treatment group (n = 23) and control group (n = 20). The treatment group received rhEPO for 10 days and oral iron administration Iron treatment. Results After 4 weeks, hemoglobin, hematocrit, reticulocyte count and quality of life scores were evaluated. The treatment group was better than the control group, the difference was statistically significant, but adverse reactions were tolerable. Conclusion The impact of rhEPO treatment of breast cancer chemotherapy-induced anemia safe and effective.